Bristol-Myers Squibb Co launches a tender offer for Kosan Biosciences Inc


US - Bristol-Myers Squibb Co (BM) completed its tender offer to acquire all the outstanding common stock of Kosan Biosciences Inc (KB), a provider of commercial research services, via a tender offer for $#.# in cash per share, or

Deal Information

Credit & Investment Research

Market Research

News